ArticleBMC biology2022
A gossypol derivative effectively protects against Zika and dengue virus infection without toxicity.
Article in BMC biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 20 citations in OpenAlex.
- Review
- Mouse models of Zika virus infection-induced placenta and fetal brain damage.Journal of animal science · 2026Review
- Natural products against Babesiosis: active compounds, molecular mechanisms, application limitations and translational development.Frontiers in cellular and infection microbiology · 2026Review
- Pathogenicity and virulence of Kyasanur Forest disease: A comprehensive review of an expanding zoonotic threat in southwestern India.Virulence · 2025Review
- Identification of Small Molecules as Zika Virus Entry Inhibitors.International journal of molecular sciences · 2025Article
- Therapeutic Use ofAnimals : an open access journal from MDPI · 2025Article
- Metabolic reprogramming in viral infections: the interplay of glucose metabolism and immune responses.Frontiers in immunology · 2025Review
- An Overview of Zika Virus and Zika Virus Induced Neuropathies.International journal of molecular sciences · 2024Review
- Envelope Protein-Targeting Zika Virus Entry Inhibitors.International journal of molecular sciences · 2024Review
- Lactate facilitated mitochondrial fission-derived ROS to promote pulmonary fibrosis via ERK/DRP-1 signaling.Journal of translational medicine · 2024Article
- The potential roles of gossypol as anticancer agent: advances and future directions.Chinese medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundZika virus (ZIKV) and dengue virus (DENV) cause microcephaly and dengue hemorrhagic fever, respectively, leading to severe problems. No effective antiviral agents are approved against infections of these flaviviruses, calling for the need to develop potent therapeutics. We previously identified gossypol as an effective inhibitor against ZIKV and DENV infections, but this compound is toxic and not suitable for in vivo treatment.
resultsIn this study, we showed that gossypol derivative ST087010 exhibited potent and broad-spectrum in vitro inhibitory activity against infections of at least ten ZIKV strains isolated from different hosts, time periods, and countries, as well as DENV-1-4 serotypes, and significantly reduced cytotoxicity compared to gossypol. It presented broad-spectrum in vivo protective efficacy, protecting ZIKV-infected Ifnar1
conclusionsOverall, our data indicate the potential for further development of this gossypol derivative as an effective and safe broad-spectrum therapeutic agent to treat ZIKV and DENV diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.